Celltrion Inc (Celltrion) manufactures biosimilars and offers contract manufacturing and development services to the manufacturers of protein- based pharmaceuticals. The company offers a process and analytical development services and clinical and commercial production capabilities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Celltrion’s research and development activities (R&D) focus on the development and process optimization of recombinant monoclonal antibodies. The company uses the mammalian cell culture and purification facilities for its process from product development to full-scale production. The company is in the process of establishing new biopharmaceutical pipeline through co-development with other major multinational pharmaceutical and biotechnology companies. The company has achieved success in developing and bringing to market the world's first antibody biosimilar products, such as Remsima (a Remicade biosimilar used to treat rheumatoid arthritis, ulcerative colitis, and other conditions), Truxima (a Rituxan biosimilar used to treat blood cancer and other illnesses), Herzuma (a Herceptin biosimilar used to treat breast cancer and other diseases), Uplima (a Humira biosimilar used to treat rheumatoid arthritis and other conditions), and Begzelma (an Avastin biosimilar). The company is also working on similar drugs, including treatments for colorectal cancer, and gradually introducing them to the global market on a country-by-country basis. It is also operating a separate BL-2 Bio Safety Level 2 Research Facility to develop new medicines for infectious viruses. In FY2022, the company spent KRW412,283.4 million on its R&D activities.